Back
Compare AU
Compare HLTH vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the VanEck Global Healthcare Leaders ETF (HLTH) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
HLTH | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 54 | 75 |
Median incremental investment | $547.55 | $742.79 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,552.01 | $1,810.48 |
Average age group | > 35 | > 35 |
Key Summary
HLTH | DRUG | |
|---|---|---|
Strategy | HLTH.AX was created on 2020-09-08 by VanEck. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 50.99m in AUM and 51 holdings. The Fund aims to provide investment returns before fees and other costs which track the performance of the Reference Index in Australian dollars. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Arrowhead Pharmaceuticals Inc (2.27 %) argenx SE ADR (2.27 %) UCB SA (2.20 %) | AUD - AUSTRALIA DOLLAR (0 %) BRL - BRAZILIAN REAL (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Health Care (100.00 %) Other (9.10 %) | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) |
Top 3 countries | United States (65.74 %) Japan (10.95 %) Denmark (8.04 %) | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) |
Management fee | 0.45 % | 0.57 % |
Key Summary
HLTH | DRUG | |
|---|---|---|
Issuer | VanEck | BetaShares |
Tracking index | MarketGrader Developed Markets ex-Australia Health Care Index - AUD | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.57 % |
Price | $11.37 | $8.54 |
Size | $50.995 million | $163.973 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 0.61 % | 1.92 % |
Market | ASX | ASX |
First listed date | 09/09/2020 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
HLTH | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 54 | 75 |
Median incremental investment | $547.55 | $742.79 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,552.01 | $1,810.48 |
Average age group | > 35 | > 35 |
Pros and Cons
HLTH | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
HLTH | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |